Skip to content

Released Oct 29, 2024, before the open

10-Q filed Nov 4, 2024, 36 days after period end · 0000078003-24-000191

Q3 2024 · 10-Q
Revenue$17.70B+31.2% vs Q3 2023+33.3% vs Q2 2024
Net Income$4.47BN/M vs Q3 2023+10,790.2% vs Q2 2024
EPS Diluted$0.78N/M vs Q3 2023+7,700.0% vs Q2 2024
Operating Cash Flowderived$6,714,000,000+94.3%
Free Cash Flowderived$6,063,000,000+129.1%
Margins · derived
Net margin25.2%+42.9 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$17.70B$13.49B$22.64B$24.04B
Net Income$4.47B-$2.38B$8.61B$8.15B
EPS Diluted$0.78-$0.42$1.51$1.42

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR